how big is Oxygenta Pharma?

As of Jun 06, Oxygenta Pharmaceutical Ltd has a market capitalization of 458.60 Cr, classifying it as a Micro Cap company, with recent net sales of 109.31 Cr and a net profit loss of 10.29 Cr. Shareholder's funds are at -20.12 Cr, with total assets of 54.46 Cr as of Mar 2024.

Market Cap: As of Jun 06, Oxygenta Pharmaceutical Ltd has a market capitalization of 458.60 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters, which is Standalone data, amounts to 109.31 Cr. In contrast, the sum of Net Profit for the same period is -10.29 Cr, indicating a loss.<BR><BR>Balance Sheet Snapshot: This is Standalone data for the latest annual period ending in Mar 2024. The Shareholder's Funds are reported at -20.12 Cr, while Total Assets stand at 54.46 Cr.

Who are in the management team of Oxygenta Pharma?

As of March 2022, the management team of Oxygenta Pharma includes Sai Sudhakar Vankineni (Managing Director), D Vidya Sagar, Muralidhar R, Sangari Kondal Reddy, Padmaja Surapureddy (Independent Directors), Kanuganti Raghavender Rao (Executive Director), Sravani Reddy Gantla, Bharath Reddy Guntuku (Additional Directors), and Dolly Mandhan (Company Secretary & Compliance Officer). Each member contributes to the company's governance and operational oversight.

As of March 2022, the management team of Oxygenta Pharma includes the following individuals:<BR><BR>1. Sai Sudhakar Vankineni - Managing Director<BR>2. D Vidya Sagar - Independent Director<BR>3. Muralidhar R - Director (Technical)<BR>4. Sangari Kondal Reddy - Independent Director<BR>5. Padmaja Surapureddy - Independent Director<BR>6. Kanuganti Raghavender Rao - Executive Director<BR>7. Sravani Reddy Gantla - Additional Director<BR>8. Bharath Reddy Guntuku - Additional Director<BR>9. Dolly Mandhan - Company Secretary & Compliance Officer<BR><BR>Each member plays a crucial role in the governance and operational oversight of the company.

Has Oxygenta Pharma declared dividend?

No Dividend History Available

Who are the peers of the Oxygenta Pharma?

Oxygenta Pharma's peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, and others. While Oxygenta Pharma has a 1-year return of 169.57%, its peers show varying management risks and growth rates, with Divi's Lab having the highest return at 51.96%.

Peers: The peers of Oxygenta Pharma are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Trident Lifeline, Gennex Lab., Sanjiv.Parant., Ambalal Sarabhai, and Sat Kartar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Cipla, Dr Reddy's Labs, and Sanjiv.Parant., while Good management risk is found at Divi's Lab., Torrent Pharma, and the rest. Below Average management risk is noted for Gennex Lab. and Ambalal Sarabhai, while Average management risk is seen at Trident Lifeline and Sat Kartar. Growth is Excellent for Sun Pharma.Inds., Cipla, Dr Reddy's Labs, Trident Lifeline, and Sat Kartar, while Below Average growth is noted for Divi's Lab. and Torrent Pharma, and the rest. Oxygenta Pharma does not qualify for any ratings in Management Risk, Growth, or Capital Structure.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Divi's Lab. at 51.96%, while the lowest is Gennex Lab. at -22.86%. Oxygenta Pharma's 1-year return of 169.57% significantly exceeds both. Additionally, Gennex Lab. and Ambalal Sarabhai have negative six-month returns.

Is Oxygenta Pharma overvalued or undervalued?

As of June 20, 2023, Oxygenta Pharma is considered overvalued and risky due to its negative financial ratios, including a PE ratio of -45.92 and a ROCE of -32.27%, despite a strong stock performance of 284.59% over the past year.

As of 20 June 2023, Oxygenta Pharma's valuation grade has moved from does not qualify to risky, indicating a significant shift in its financial standing. The company appears to be overvalued, given its negative PE ratio of -45.92, an EV to EBITDA ratio of -52.33, and a ROCE of -32.27%. These ratios suggest that the company's earnings and capital efficiency are under severe pressure.<BR><BR>In comparison to its peers, Oxygenta Pharma's valuation metrics are starkly unfavorable. For instance, Sun Pharmaceutical Industries Ltd. has a PE ratio of 35.25, while Cipla Ltd. boasts a PE of 22.99, both indicating a healthier financial position. Additionally, Oxygenta's PEG ratio stands at 0.00, which is significantly lower than the industry averages. Despite its recent stock performance, which has outpaced the Sensex with a 1-year return of 284.59% versus 7.60%, the underlying financial ratios suggest that the stock is not supported by fundamental value, reinforcing the conclusion that it is overvalued.

What is the technical trend for Oxygenta Pharma?

As of May 12, 2025, Oxygenta Pharma's trend has shifted to bullish, supported by positive weekly MACD and KST indicators, although caution is advised due to a bearish monthly RSI, despite a strong 1Y return of 274.62%.

As of 12 May 2025, the technical trend for Oxygenta Pharma has changed from mildly bullish to bullish. The weekly MACD and KST are both bullish, supporting the bullish stance. The daily moving averages also indicate a bullish trend. However, the monthly RSI is bearish, which suggests some caution. Overall, the strength of the bullish trend is reinforced by the performance metrics, with significant returns over various periods, particularly the 1Y return of 274.62%.

What does Oxygenta Pharma do?

Oxygenta Pharmaceutical Ltd manufactures pharmaceutical preparations and organic fine chemicals, classified as a Micro Cap company. As of March 2025, it reported net sales of 495 Cr and a net loss of 22 Cr.

Overview:<BR>Oxygenta Pharmaceutical Ltd is engaged in the manufacturing of various classes of drugs, including pharmaceutical preparations and organic fine chemicals, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History:<BR>Oxygenta Pharmaceutical Ltd was incorporated in 1990 as a Private Limited Company and converted into a Limited Company in 1993. The company changed its name from S.S. Organics Ltd. to Oxygenta Pharmaceutical Limited in the fiscal year 2021-22. The most recent quarterly results reported net sales and net profit for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 495 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -22 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 412 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: N/A <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -2.42 <BR>Return on Equity: 39.08% <BR>Price to Book: -15.74 <BR><BR>Contact Details:<BR>Address: Survey No 252/1 Aroor Village, Sadasivapet Mandal Medak Telangana : 502291 <BR>Tel: 91-08455-250080/250280 <BR>Email: info@ssorganics.co.in <BR>Website: http://oxygentapharma.com

Who are the top shareholders of the Oxygenta Pharma?

The top shareholders of Oxygenta Pharma are M V S Prasad Reddy with 25.56%, and Sravani Reddy Gantla as the highest public shareholder at 12.13%. Individual investors own 43.93%, with no pledged promoter holdings or foreign institutional investors involved.

The top shareholders of Oxygenta Pharma include M V S Prasad Reddy, who holds the largest stake at 25.56%. The highest public shareholder is Sravani Reddy Gantla, with a holding of 12.13%. Additionally, individual investors collectively own 43.93% of the company. There are no pledged promoter holdings, and the company does not have any foreign institutional investors (FIIs) involved.

When is the next results date for Oxygenta Pharma?

Oxygenta Pharma will announce its results on 07 November 2025.

Oxygenta Pharma is scheduled to declare its results on 07 November 2025.

Are Oxygenta Pharma latest results good or bad?

Oxygenta Pharma's latest results are concerning, showing a net loss of ₹6.11 crores and a 69.42% drop in revenue from the previous quarter, indicating severe operational challenges and a negative net worth of ₹25.02 crores. Overall, these results are bad and suggest a critical need for restructuring.

Oxygenta Pharma's latest results are quite concerning. In Q2 FY26, the company reported a net loss of ₹6.11 crores, which is a significant deterioration compared to the previous quarter, reflecting a staggering 349.63% decline quarter-on-quarter. Revenue also dropped sharply by 69.42% from ₹49.47 crores in Q1 FY26 to just ₹15.13 crores, despite a year-on-year growth of 19.89%.<BR><BR>The operating margin has plunged to -45.14%, marking the worst performance in seven quarters, indicating severe operational challenges. Additionally, the profit after tax (PAT) margin fell to -40.38%, worsening from -4.35% in the previous quarter.<BR><BR>Overall, these results highlight a company in acute financial distress, with significant revenue volatility and a negative net worth of ₹25.02 crores. The financial trajectory suggests fundamental issues that could jeopardize its long-term viability. Therefore, the latest results can be characterized as bad, reflecting a critical need for restructuring and operational improvement.

Should I buy, sell or hold Oxygenta Pharma?

How has been the historical performance of Oxygenta Pharma?

Oxygenta Pharma experienced significant sales growth, reaching 109.30 Cr in March 2025, but faced rising expenditures leading to negative operating profit of -10.00 Cr and worsening profitability metrics. Total liabilities increased to 72.62 Cr, with negative shareholder's funds at -25.02 Cr, indicating ongoing financial distress despite a slight improvement in cash flow from operations.

Answer:<BR>The historical performance of Oxygenta Pharma shows significant fluctuations in its financial metrics over the years, with a notable increase in net sales in March 2025 reaching 109.30 Cr, up from 39.64 Cr in March 2024 and 30.99 Cr in March 2023. However, the company has faced challenges with total expenditure, which rose to 119.30 Cr in March 2025 from 49.34 Cr in March 2024, leading to an operating profit of -10.00 Cr in March 2025, slightly worse than -9.70 Cr in the previous year. The profit before tax also declined to -14.35 Cr in March 2025 from -13.87 Cr in March 2024, while the profit after tax was -10.30 Cr, worsening from -3.48 Cr in March 2024. The company's total liabilities increased to 72.62 Cr in March 2025 from 54.46 Cr in March 2024, with total debt at 62.23 Cr. Shareholder's funds remained negative at -25.02 Cr in March 2025, indicating ongoing financial distress. Cash flow from operating activities showed a slight improvement to 2.00 Cr in March 2025, compared to -13.00 Cr in March 2024, but cash flow from investing activities was negative at -11.00 Cr.<BR><BR>Breakdown:<BR>Oxygenta Pharma's financial trajectory reflects a complex mix of growth and challenges. The company's net sales surged to 109.30 Cr in March 2025, a significant increase from previous years, yet this growth was overshadowed by a sharp rise in total expenditure, which reached 119.30 Cr, resulting in an operating profit of -10.00 Cr. This trend continued with a profit before tax of -14.35 Cr and a profit after tax of -10.30 Cr, indicating deteriorating profitability. The total liabilities climbed to 72.62 Cr, with total debt at 62.23 Cr, while shareholder's funds remained negative at -25.02 Cr, highlighting ongoing financial difficulties. Despite a positive cash flow from operating activities of 2.00 Cr, the overall financial health of Oxygenta Pharma appears precarious as it navigates through these challenges.

Which are the latest news on Oxygenta Pharma?

Which are the latest news on Oxygenta Pharma?

Why is Oxygenta Pharma falling/rising?

As of 21-Dec, Oxygenta Pharmaceutical Ltd's stock price is at 55.00, with a recent upward change of 0.94%. However, the stock has experienced significant declines over the year and recent weeks, indicating a bearish outlook and decreased investor confidence.

As of 21-Dec, Oxygenta Pharmaceutical Ltd's stock price is currently at 55.00, reflecting a change of 0.51 (0.94%) upward. Despite this recent increase, the stock has shown a significant decline over various periods, with a year-to-date drop of 37.12% and a one-year decline of 40.20%. <BR><BR>The stock's performance over the past week and month also indicates a downward trend, with losses of 8.56% and 8.82%, respectively. Furthermore, Oxygenta Pharma is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish outlook. <BR><BR>Investor participation has notably decreased, with a delivery volume of 2.38k on December 18, which is down by 95.12% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors. Although the stock is currently liquid enough for trading, the overall trends indicate that Oxygenta Pharma is experiencing more challenges than gains, contributing to its recent price movements.

Why is Oxygenta Pharma falling/rising?

As of 22-Dec, Oxygenta Pharmaceutical Ltd's stock price is at 55.00, showing a slight increase but overall underperforming with a year-to-date decline of 37.12%. The stock is trading below moving averages, indicating a bearish trend, and investor interest has significantly decreased.

As of 22-Dec, Oxygenta Pharmaceutical Ltd's stock price is currently at 55.00, reflecting a slight increase of 0.01 (0.02%). Despite this minor rise, the stock has been underperforming in the market, as evidenced by its performance over various periods. Over the past week, the stock has decreased by 1.10%, and over the last month, it has fallen by 8.38%. Year-to-date, the stock is down 37.12%, and over the past year, it has declined by 38.98%. <BR><BR>In contrast, the benchmark Sensex has shown positive returns, increasing by 0.42% over the past week and 9.51% year-to-date. This stark difference highlights the stock's underperformance relative to the broader market. Furthermore, Oxygenta Pharma has been trading below its moving averages across multiple time frames, indicating a bearish trend. <BR><BR>Investor participation has also significantly decreased, with delivery volume dropping by 94.09% compared to the 5-day average, suggesting a lack of interest among investors. Although the stock has gained for the last two days, with a total return of 0.94%, this is not enough to offset the overall negative trends observed in both short-term and long-term performance metrics. Thus, while there is a minor uptick in the stock price, the broader context indicates that Oxygenta Pharma is facing significant challenges that contribute to its overall decline.

Why is Oxygenta Pharmaceutical Ltd falling/rising?

As of 23-Dec, Oxygenta Pharmaceutical Ltd's stock price is at 54.55, reflecting a decline of 0.78%. The stock has significantly underperformed against the Sensex, with a year-to-date drop of 37.64% and a recent decrease in investor interest.

As of 23-Dec, Oxygenta Pharmaceutical Ltd's stock price is falling, currently at 54.55, which reflects a decrease of 0.43 or 0.78%. The stock has underperformed compared to the benchmark Sensex, which has increased by 1.00% over the past week, while Oxygenta's stock has declined by 0.82%. Over the past month, the stock has experienced a significant drop of 9.13%, contrasting with a modest gain of 0.34% in the Sensex.<BR><BR>Year-to-date, Oxygenta's stock has plummeted by 37.64%, while the Sensex has risen by 9.45%. This trend continues over the past year, with Oxygenta down 38.25% compared to an 8.89% increase in the Sensex. The stock's performance over shorter periods also indicates a downward trajectory, as it has been losing for the last two days, with a total decline of 0.8%.<BR><BR>Additionally, Oxygenta is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. Investor participation has also decreased significantly, with delivery volume dropping by 87.78% against the 5-day average, indicating reduced interest in the stock. Furthermore, the stock is close to its 52-week low, being only 4.49% away from the low of Rs 52.1. All these factors contribute to the current decline in Oxygenta Pharmaceutical Ltd's stock price.

Why is Oxygenta Pharmaceutical Ltd falling/rising?

As of 24-Dec, Oxygenta Pharmaceutical Ltd's stock price is at Rs 54.00, down 1.01%, and has significantly underperformed the Sensex, with a year-to-date decline of 38.26%. The stock is nearing its 52-week low and shows a bearish trend with decreased investor participation.

As of 24-Dec, Oxygenta Pharmaceutical Ltd's stock price is falling, currently at Rs 54.00, which reflects a decrease of Rs 0.55 or 1.01%. The stock has been underperforming significantly compared to the benchmark Sensex, with a 1-week decline of 2.69% while the Sensex gained 1.00%. Over the past month, the stock has dropped by 9.34%, contrasting with a modest 0.60% increase in the Sensex. Year-to-date, Oxygenta's stock has plummeted by 38.26%, while the Sensex has risen by 9.30%. <BR><BR>The stock is also close to its 52-week low, being just 3.52% away from Rs 52.1. It has experienced a consecutive decline over the last three days, resulting in a total drop of 1.8% during this period. Furthermore, Oxygenta is trading below its moving averages across various timeframes, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a bearish trend. <BR><BR>Investor participation has notably decreased, with a delivery volume of only 306 on December 23, which is a staggering 94.93% lower than the 5-day average delivery volume. This decline in trading activity suggests a lack of interest from investors, contributing to the downward pressure on the stock price. Overall, these factors collectively indicate that Oxygenta Pharmaceutical Ltd is experiencing a decline in its stock price.

Why is Oxygenta Pharmaceutical Ltd falling/rising?

As of 25-Dec, Oxygenta Pharmaceutical Ltd's stock price is Rs 54.00, down 1.01%, and has significantly underperformed the Sensex with a year-to-date decline of 38.26%. The stock is nearing its 52-week low and has shown reduced investor interest, contributing to its ongoing downturn.

As of 25-Dec, Oxygenta Pharmaceutical Ltd's stock price is falling, currently at Rs 54.00, which reflects a decrease of Rs 0.55 or 1.01%. The stock has been underperforming significantly compared to the benchmark Sensex, with a 1-week decline of 2.69% while the Sensex gained 1.00%. Over the past month, the stock has dropped 9.34%, contrasting with a modest 0.60% increase in the Sensex.<BR><BR>Year-to-date, Oxygenta's performance is particularly concerning, showing a decline of 38.26%, while the Sensex has risen by 9.30%. Over the past year, the stock has decreased by 40.07%, again underperforming the Sensex, which has increased by 8.84%. Although the stock has shown strong growth over the longer term, with a 3-year increase of 96.01% and a remarkable 5-year increase of 639.73%, the recent trends indicate a significant downturn.<BR><BR>Today's performance indicates that the stock is close to its 52-week low, being only 3.52% away from Rs 52.1. It has been on a consecutive decline for the last three days, accumulating a total drop of 1.8% during this period. Additionally, Oxygenta is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend.<BR><BR>Investor participation has also decreased, with delivery volume on December 23 falling by 94.93% compared to the 5-day average, indicating reduced interest in the stock. Overall, these factors contribute to the ongoing decline in Oxygenta Pharmaceutical Ltd's stock price.

Why is Oxygenta Pharmaceutical Ltd falling/rising?

As of 26-Dec, Oxygenta Pharmaceutical Ltd's stock price is stable at 54.10 but has experienced significant declines, dropping 38.15% year-to-date and 41.13% over the past year, indicating underperformance compared to the benchmark Sensex. The stock is trading below its moving averages and near its 52-week low, suggesting bearish sentiment and declining investor interest.

As of 26-Dec, Oxygenta Pharmaceutical Ltd's stock price is currently stable at 54.10, showing no change from the previous trading session. However, the stock has been experiencing a downward trend over various time periods. Over the past week, it has decreased by 1.62%, and in the last month, it has fallen by 9.83%. Year-to-date, the stock has declined significantly by 38.15%, and over the past year, it has dropped 41.13%. <BR><BR>In contrast, the benchmark Sensex has shown positive performance, increasing by 8.83% year-to-date and 8.37% over the past year. This stark difference in performance indicates that Oxygenta Pharmaceutical Ltd is underperforming relative to the broader market.<BR><BR>Additionally, the stock is currently trading lower than its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically signals a bearish trend. The stock is also close to its 52-week low, being just 3.7% away from it, which may further indicate weakness in its price performance.<BR><BR>Investor participation appears to be declining, as evidenced by a 12.62% drop in delivery volume compared to the 5-day average. This reduction in trading activity could suggest waning interest among investors, contributing to the stock's inability to rise.<BR><BR>Overall, the combination of significant declines in stock price over various periods, underperformance against the benchmark, lower trading volumes, and trading below moving averages all point to a bearish sentiment surrounding Oxygenta Pharmaceutical Ltd.